Yongping Zhang

Yongping Zhang

Auto-generated profile, based on publicly available information

Yongping Zhang

Department of Hematology Aerospace Center Hospital Beijing China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2017 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
YZYongping Zhang
Yongping Zhang
XZXingying Zhang
Xingying Zhang
CCChen Cheng
Chen Cheng
WMWei Mu
Wei Mu
XLXiaojuan Liu
Xiaojuan Liu
HWHaoyi Wang
Haoyi Wang

10 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JLJiangshan Lian
Jiangshan Lian
MAMunire Adilijiang
Munire Adilijiang
CCCaihua Chang
Caihua Chang
HJHaiyin Jiang
Haiyin Jiang
YZYongping Zhang
Yongping Zhang

18 November 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PCPing Chen
Ping Chen
WWWeiyi Wang
Weiyi Wang
YZYongping Zhang
Yongping Zhang
YYYaozong Yuan
Yaozong Yuan
YWYunlin Wu
Yunlin Wu

25 August 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
QHQi Hao
Qi Hao
XLXinyue Liu
Xinyue Liu
YZYongping Zhang
Yongping Zhang
DZDongmei Zhang
Dongmei Zhang
BLBoran Li
Boran Li
JWJingbo Wang
Jingbo Wang
We retrospectively analyzed data from 197 patients with refractory or relapsed acute myeloid leukemia (r/rAML) who underwent allo‐HCT between January 2013 and February 2020 in our center (patients with promyelocytic leukemia were excluded). Of all patients, 86 achieved a complete morphological remission (CR) before transplant, while 111 failed to do so (NR). In the CR group, 32 patients displayed minimal residual disease (MRD‐positive). According to their immunophenotype pre‐HCT, we divided the MRD‐positive group and NR group into three subgroups: MRD 0+ group (without any antigen abnormal expression of CD7+, CD56+, CD38−, or HLA‐DR−) 28 patients, MRD 1+ group (with one abnormal antigen expression of CD7+, CD56+, CD38−, or HLA‐DR−) 63 patients, MRD 2+ group (with two or more abnormal antigens expression of CD7+, CD56+, CD38‐, or HLA‐DR‐) 52 patients. 3‐year estimates of disease‐free survival (DFS) for MRD 0+, MRD 1+ and MRD 2+ patients were 59.5 ± 9.5%, 29.9 ± 6.1%, and 9.4 ± 5.1%, and 3‐year estimates of overall survival (OS) were 59.5 ± 9.5%, 34.5 ± 6.3%, and 14.5 ± 10.8%, respectively. Multivariate analysis adjusted for genetic risk, blast cell level, secondary disease, age, sex, and donor relationship pre‐HCT, the hazard ratios of abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38‐ were 6.69 (range 2.08–21.52; p = 0.001) for DFS, 2.24 (range 1.21–4.14; p = 0.010) for OS, and 7.18 (range 2.23–23.10; p = 0.001) for relapse compared with CD7−, CD56−, HLA‐DR+, and CD38+ patients. Our finding suggested that abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38− is associated with poor outcomes, and the more number of abnormal antigens expression predict worse outcomes.